SCHEMBL4770196

SCHEMBL4770196

Cc1occc1S(=O)(=O)N(C(=O)[CH]CC(C)C(N)=O)[C@H]1CCCNCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4907047 0.91
SCHEMBL6591177 0.85 CTSK (0.33)
SCHEMBL4761958 0.84 PSEN1 (0.31)
SCHEMBL6592601 0.84
SCHEMBL6602697 0.83 CTSK (0.36)
SCHEMBL6591381 0.83 PSEN1 (0.34)
SCHEMBL4763000 0.82 PSEN1 (0.36)
SCHEMBL7536966 0.82 ALDH1A1 (0.34)
SCHEMBL4768440 0.82
SCHEMBL6607371 0.82 TSHR (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1320370-A4 METHOD OF TREATMENT SMITHKLINE BEECHAM CORP (US) 2008-10-22 EP disclosed
EP-1320370-A1 METHOD OF TREATMENT SmithKline Beecham Corporation (US) 2003-06-25 EP disclosed
US-20030044399-A1 Method of treatment SMITHKLINE BEECHAM CORPORATION 2003-03-06 US disclosed
WO-2002017924-A1 METHOD OF TREATMENT SMITHKLINE BEECHAM CORPORATION (GB) 2002-03-07 WO disclosed